Innovent and Eli Lilly Report Real-World Analysis of Sintilimab and Bevacizumab Biosimilar for Hepatocellular Carcinoma
Shots:
- The real-world analysis evaluating sintilimab (200mg, q3w) + bevacizumab biosimilar (15mg/kg) in patients with advanced HCC
- The results confirmed the promising efficacy, tolerable toxicity, and cost-effectiveness in Chinese patients with aHCC who received sintilimab + bevacizumab, m-OS & m-PFS were 344.00 & 238.00 days, AEs were reported in 51.5%, incl. 9 patients with grade ≥3, life-year and quality-adjusted LY were 1.97 and 2.92
- The results published in the Journal of Cancer Research and Clinical Oncology demonstrated the clinical benefits of sintilimab + bevacizumab. At the time of best response status, no patients achieved CR; PR in 8 patients and SC (51 patients); 9 experienced disease progression (ORR, 11.8%; DCR, 86.8%), treatment-related AEs (51.5%)
Ref: Center For Biosimilars | Image: Innovent
Related News:- HUTCHMED Receives the NMPA’s Breakthrough Therapy Designation for Fruquintinib + Sintilimab to Treat Advanced Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
